-
Mashup Score: 0Tracking the Mutations of the Latest Omicron Variants - 2 year(s) ago
The BA.2 COVID-19 variant maintained the mutations necessary for viral entry, but developed an increased ability to evade neutralization by monoclonal antibodies.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 3Eurosurveillance | Volume 27, Issue 18 - 2 year(s) ago
eurosurveillance.org is the online home of Eurosurveillance, Europe’s journal on infectious disease surveillance, epidemiology, prevention and control.
Source: www.eurosurveillance.orgCategories: HIV/AIDS, Latest HeadlinesTweet
-
Mashup Score: 0
Immune escape for the BA.2 subvariant, or “stealth Omicron,” was not as severe as that of the original Omicron variant, a new study suggests.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 0Monoclonal Antibodies More Effectively Neutralize BA.2 Than BA.1 - 2 year(s) ago
Though many monoclonal antibodies were paused after demonstrated to be insufficient against the BA.1 Omicron subvariant, they may be more effective against BA.2.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 21
Experts share their tips ahead of the next wave.
Source: TODAY.comCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 4
The Omicron subvariant BA.2 is causing an increase in infections, especially in Manhattan. But hospitalizations have yet to rise.
Source: www.nytimes.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
The Assistant Secretary for Preparedness and Response (ASPR) announced a pause in sotrovimab distribution in regions where BA.2 is the dominant COVID-19 variant, citing evidence that the monoclonal antibody therapy would not effectively neutralize the BA.2 Omicron variant.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 9
The Assistant Secretary for Preparedness and Response (ASPR) announced a pause in sotrovimab distribution in regions where BA.2 is the dominant COVID-19 variant, citing evidence that the monoclonal antibody therapy would not effectively neutralize the BA.2 Omicron variant.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 0Tracking the BA.2 Sub-Variant of Omicron - 2 year(s) ago
By now, you’ve no doubt heard that scientists are tracking a rise in COVID-19 cases in Europe caused by BA.2, a sub-variant of the omicron variant of COVID-19. As of mid-March, experts say BA.2 makes up about a third of the cases of COVID-19 in the United States. But what does that mean and is it a cause for concern about another surge? Atrium Health Infectious Diseases physician, Dr. Anupama…
Source: atriumhealth.orgCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 2
The monoclonal antibody sotrovimab is no longer authorized by the FDA to treat COVID-19 in certain U.S. regions with high frequency of the omicron BA.2 subvariant. In a statement released March 25, the FDA said it was limiting the use of sotrovimab (Xevudy, GlaxoSmithKline) in some U.S. regions, mostly along the east coast, following data showing that the authorized dose of the monoclonal
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet
Genomic sequencing of the Omicron #BA2 variant revealed it contains many new mutations, but also revertant mutations, making it more stable and infectious. https://t.co/EsLT7GkmtQ